Recent studies have focused on the intersection of GLP|GIP|glucagon receptor agonist therapies and dopaminergic signaling. While GIP agonists are widely employed for managing type 2 diabetes, their potential effects on reinforcement circuits, specifically influenced by dopamine pathways, are receiving substantial focus. This report presents a brief